Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Oct 19;6:35383. doi: 10.1038/srep35383

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

CDK4 expression was assessed by Kaplan-Meier survival analysis for 5-year overall survival outcome in 1,117 breast cancer patients (A) as well as 5-year early relapse free survival outcome in 3,554 breast cancer patients (B). The survival rates were analyzed using median splits of the patients, based on CDK4 expression levels. High CDK4 expression is represented in red. Hazard ratio (HR). (C–F) Correlation analysis between CDK4 expression and relapse free survival outcomes in ER positive, ER negative, basal-like and lymph node positive breast cancer patients. (G) CDK4 expression correlates with a high signature score for a set of genes that predicts for distant recurrence in tamoxifen-treated patients with lymph node-negative, ER positive breast cancer. (H) CDK4 expression correlates with a high signature score for a set of genes that predicts for poor distant metastasis outcome in the early-stage of TNBC patients.